Arxx Therapeutics
www.arxxtx.comFounded in 2018, Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
Read moreFounded in 2018, Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
Read moreCountry
City (Headquarters)
Oslo
Industry
Employees
11-50
Founded
2018
Social
Employees statistics
View all employeesPotential Decision Makers
Vice President Clinical Research
Email ****** @****.comPhone (***) ****-****Board Member
Email ****** @****.comPhone (***) ****-****Board Member
Email ****** @****.comPhone (***) ****-****Chairman of the Board
Email ****** @****.comPhone (***) ****-****
Technologies
(5)
Reach decision makers at Arxx Therapeutics
Free credits every month!
Arxx Therapeutics FAQ
Oslo, Norway
Biotechnology Research